Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity

British Journal of Clinical Pharmacology

Volumn 48, Issue 4, 1999, Pages 564-572

  Brynne, N ^a   Forslund, C ^b   Hallen B ^a   Gustafsson, L L ^b   Bertilsson, L ^b  

^a Pharmacia and Upjohn AB ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antimuscarinic; CYP2D6; CYP3A4; Drug interaction; Ketoconazole; Tolterodine; Urinary incontinence

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DRUG METABOLITE; FUNGOTAL; KETOCONAZOLE; TOLTERODINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ENZYME DEFICIENCY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTIFUNGAL AGENTS; BENZHYDRYL COMPOUNDS; CRESOLS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; KETOCONAZOLE; MALE; MIXED FUNCTION OXYGENASES; MUSCARINIC ANTAGONISTS; PHENOTYPE; PHENYLPROPANOLAMINE; TIME FACTORS;

EID: 0032847792     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00053.x     Document Type: Article

References (27)

1. 1 Rentzhog L, Stanton SL, Cardozo L, Fall M, Nelson E, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study. Br J Urol 1998; 81: 42-48.
2. 2 Jonas U, Höfner K, Madersbacher H, Holmdahl TH. and the participants of the international study group. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997; 15: 144-151.
3. 3 Van Kerrebroeck PEVA, Amarenco G, Thüroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998; 17: 499-512.
4. 4 Nilvebrant L, Andersson K-E, Gillberg P-G, Stahl M, Sparf B. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207.
5. 5 Brynne N, Stahl MMS, Hallén B et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 287-295.
6. 6 Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 1998; 63: 529-539.
7. 7 Postlind H, Danielsson Å, Lindgren A, Andersson SHG. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26: 289-293.
8. 8 Nilvebrant L, Gillberg P-G, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 169-172.
9. 9 Bertilsson L, Dahl M-L. Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-223.
10. 10 Påhlman I, Gozzi P. Protein binding of tolterodine and its major metaboltes in human and several animal species. Biopharm Drug Dispos 1999; 20: 91-99.
11. 11 Brown MW, Maldonado AL, Meredith CG, Speeg KV. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther 1985; 3: 290-297.
12. 12 Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992; 6: 752-758.
13. 13 Vahre A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-607.
14. 14 Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen PJ. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45: 191-193.
15. 15 Palmér L, Andersson L, Andersson T, Stenberg U. Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry. J Pharm Biomed Anal 1997; 16: 155-165.
16. 16 Andersson T, Svanström C, Palmér L. Quantification of tolterodine metabolites in serum using electrospray ionisation tandem mass spectrometry (LC-EC MS/MS). 8th International Symposium on Pharmaceutical and Biomedical Analysis, Orlando, May 1997 (Abstract).
17. 17 Riley CM, James MO. Determination of ketoconazole in the plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography. J Chromatogr 1986; 377: 287-294.
18. 18 Gibaldi M, Perrier D. Pharmacokinetics 2nd edn. New York: Marcel Dekker 1982.
19. 19 Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications 3rd edn, Philadelphia: Williams & Wilkins 1995.
20. 20 Tozer T. Implications of altered plasma protein binding in disease states. In Pharmacokinetic basis for drug treatment, eds. Benet LZ, Massoud N, Gambertoglio JG, New York: Raven Press 1984.
21. 21 Blyden GT, Abemethy DR, Greenblatt DJ. Ketoconazole does not impair the antipyrine clearance in humans. Int J Clin Pharmacol Ther Toxicol 1986; 24: 225-226.
22. 22 Glynn AM, Slaughter RL, Brass C, Dámbrosio R, Jusko WJ. Effects of ketoconazole in methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther 1986; 39: 654-659.
23. 23 Salphati L, Benet LZ, Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 1998; 56: 308-313.
24. 24 Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24: 475-490.
25. 25 Ameer B, Weintraub R. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33: 103-121.
26. 26 Brynne N, Svanström C, Åberg-Wistedt A, Hallén B, Bertilsson L. Fluoxetine inhibits the metabolism of tolterodine pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol 1999; 48: 553-563.
27. 27 Larsson G, Hallén B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urol 1999; 53: 990-998.